Latest Period
Q4 2025
Security Snapshot
Nuvectis Pharma, Inc. - COM (NVCT) Institutional Ownership
CUSIP: 67080T108
13F Institutional Holders and Ownership History from Q1 2022 to Q1 2026
Institutions Reporting
47
Shares (Excl. Options)
4,238,693
Price
$7.55
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / COM
- Symbol
- NVCT on Nasdaq
- Price per share
- $8.16
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 4,238,693
- Total reported value
- $32,029,225
- % of total 13F portfolios
- 0%
- Share change
- +543,149
- Value change
- +$4,308,822
- Number of holders
- 47
- Price from insider filings
- $8.16
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- NVCT - Nuvectis Pharma, Inc. - COM is tracked under CUSIP 67080T108.
- 47 institutions reported positions in Q4 2025.
- Schedule 13D/13G significant owner rows are not currently available.
What Changed
- Holder count moved from 47 to 26 between Q4 2025 and Q1 2026.
- Reported value moved from $32,029,225 to $16,975,029.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 47 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 67080T108?
CUSIP 67080T108 identifies NVCT - Nuvectis Pharma, Inc. - COM in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 67080T108:
As of 31 Dec 2025, 47 institutional investors reported holding 4,238,693 shares of Nuvectis Pharma, Inc. - COM (NVCT).
Institutional Holders of Nuvectis Pharma, Inc. - COM (NVCT) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 2,196,202 | $16,975,029 | +$641,719 | $7.73 | 26 |
| 2025 Q4 | 4,238,693 | $32,029,225 | +$4,308,822 | $7.55 | 47 |
| 2025 Q3 | 3,694,801 | $22,240,671 | +$875,366 | $6.02 | 52 |
| 2025 Q2 | 3,242,656 | $24,212,274 | +$8,414,990 | $7.47 | 46 |
| 2025 Q1 | 2,047,125 | $20,049,463 | +$7,527,323 | $9.77 | 33 |
| 2024 Q4 | 1,320,778 | $7,145,290 | +$1,393,786 | $5.41 | 31 |
| 2024 Q3 | 1,049,389 | $6,599,330 | -$771,215 | $6.29 | 31 |
| 2024 Q2 | 1,205,075 | $7,627,698 | -$2,433,916 | $6.33 | 40 |
| 2024 Q1 | 1,561,977 | $12,807,385 | +$393,490 | $8.20 | 40 |
| 2023 Q4 | 1,513,319 | $12,620,464 | +$1,886,095 | $8.34 | 36 |
| 2023 Q3 | 1,277,304 | $16,463,587 | +$85,915 | $12.89 | 33 |
| 2023 Q2 | 1,252,927 | $20,033,227 | +$12,444,259 | $15.97 | 37 |
| 2023 Q1 | 483,928 | $6,343,634 | -$3,188,708 | $13.11 | 13 |
| 2022 Q4 | 983,925 | $7,378,970 | +$968,656 | $7.50 | 11 |
| 2022 Q3 | 1,417,003 | $10,047,000 | +$5,345,357 | $7.09 | 9 |
| 2022 Q2 | 643,014 | $7,201,000 | +$370,284 | $11.20 | 10 |
| 2022 Q1 | 628,110 | $4,654,000 | +$4,654,000 | $7.40 | 7 |